LEFT ATRIUM AND MODERN VIEWS ON PATHOGENESIS OF ESSENTIAL HYPERTENSION
https://doi.org/10.18705/1607-419X-2013-19-1-18-26
Abstract
The reviewed data concerning modern performance about the changes of left atrium in hypertension are cited in the paper. Haemodynamic, neurohumoral, molecular, electrophysiologic pathogenic factors of left atrium structural and functional remodeling in this disease are discussed. Changes of left atrium as hypertensive target organ presents an essential (and as a rule the earliest) sign of cardiovascular continuum.
About the Authors
A. V. Barsukov
Military Medical Academy named after S.M. Kirov, St Petersburg
Russian Federation
Corresponding author: Military Medical Academy named after S.M. Kirov, 6 Lebedev st., St Petersburg, Russia, 194044. E-mail: avbarsukov@yandex.ru (Anton V. Barsukov, MD, PhD, the 2nd Professor at Hospitаl Therapy Department at Medical Military Academy named after S.M. Kirov).
Russian Federation
Corresponding author: Military Medical Academy named after S.M. Kirov, 6 Lebedev st., St Petersburg, Russia, 194044. E-mail: avbarsukov@yandex.ru (Anton V. Barsukov, MD, PhD, the 2nd Professor at Hospitаl Therapy Department at Medical Military Academy named after S.M. Kirov).
D. V. Glukhovskoy
Military Medical Academy named after S.M. Kirov, St PetersburgMilitary Medical Academy named after S.M. Kirov, St Petersburg
Russian Federation
Russian Federation
N. P. Zobnina
Military Medical Academy named after S.M. Kirov, St Petersburg
Russian Federation
Russian Federation
M. S. Talantseva
Military Medical Academy named after S.M. Kirov, St Petersburg
Russian Federation
Russian Federation
T. S. Sveklina
Military Medical Academy named after S.M. Kirov, St Petersburg
Russian Federation
Russian Federation
References
1. Krahn A. D., Manfreda J., Tate R.B. et al. The natural history of atrial fi brillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study // Am. J. Med. — 1995. — Vol. 98, № 5. — P. 476–484.
2. Wachtell K., Lehto M., Gerdts E. et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study // J. Am. Coll. Cardiol. — 2005. — Vol. 45, № 5. — P. 712–719.
3. Du X., Ninomiya T., Abadir E. et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fi brillation: results of the ADVANCE study // Eur. Heart J. — 2009. — Vol. 30, № 9. — P. 1128–1135.
4. Psaty B.M., Manolio T.A., Kuller L.H. et al. Incidence of and risk factors for atrial fi brillation in older adults // Circulation. — 1997. — Vol. 96, № 7. — P. 2455–2461.
5. Kannel W.B., Wolf P.A., Benjamin E.J. et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates // Am. J. Cardiol. —1998. — Vol. 82, № 8А. — P. 2N–9N.
6. Verdecchia P., Reboldi G.P., Gattobigio R. et al. Atrial fibrillation in hypertension: predictors and outcome // Hypertension. — 2003. — Vol. 41, № 2. — P. 218–223.
7. Vaziri S.M., Larson M.G., Lauer M.S. et al. Infl uence of blood pressure on left atrial size. The Framingham Heart Study // Hypertension. — 1995. — Vol. 25, № 6. — P. 1155–1160.
8. Galderisi M., Petrocelli A., Fakher A. et al. Infl uence of night time blood pressure on left atrial size in uncomplicated arterial systemic hypertension // Am. J. Hypertens. — 1997. — Vol. 10, № 8. — P. 836–842.
9. Aksnes T. A., Schmieder R.E., Kjeldsen S.E. et al. Impact of n heart failure in high risk hypertension (from the VALUE Trial) // Am. J. Cardiol. — 2008. — Vol. 101, № 5. — P. 634–638.
10. Barsukov A., Bagaeva Z., Lokshina T. et al. Echocardiographic data in overweight essential hypertensive patients with different types of left ventricular hypertrophy // J. Hypertens. — 2010. — Vol. 28 (Suppl). — P. 568.
11. Pearlman N.W., Meyers A.D., Sullivan W.G. Muscle fi berorientation and connective tissue content in the hypertrophied human heart // Lab. Invest. — 1982. — Vol. 46, № 2. — P. 158–164.
12. Gerdts E., Oikarinen L., Palmieri V. et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study // Hypertension. — 2002. — Vol. 39, № 3. — P. 739–743.
13. Gottdiener J.S., Reda D.J., Williams D.W. et al. Effect of single-drug therapy on reduction of left atrial size in mild to moderate hypertension: comparison of six antihypertensive agents // Circulation. — 1998. — Vol. 98, № 2. — P. 140–148.
14. Miller J.T., O’Rourke R.A., Crawford M.H. Left atrial enlargement: an early sign of hypertensive heart disease // Am. Heart J. — 1988. — Vol. 116. — P. 1048–1051.
15. Rodrigues A.C., Scannavacca M.L., Caldas M.A. et al. Left atrial function after ablation for paroxysmal atrial fi brillation // Am. J. Cardiol. — 2009. — Vol. 103, № 3. — P. 395–398.
16. Saraiva R.M., Yamano T., Matsumra Y. et al. Left atrial function assessed by real-time 3-dimensional echocardiography is related to right ventricular systolie pressure in chronic mitral regurgitation // Am. Heart J. — 2009. — Vol. 158, № 2. — P. 309–316.
17. Anvar A.M., Geleijnse M.L., Soliman O.I. et al. Left atrial Frank-Starling law assessed by real-time, three-dimensional echocardiographic left atrial volume changes // Heart. — 2007. — Vol. 93, № 11. — P. 1393–1397.
18. Бартош Ф.Л., Бартош Л.Ф., Адонина Т.С. Особенности диастолической функции левого желудочка у больных гипертонической болезнью с фибрилляцией предсердий // Артериальная гипертензия. — 2012. — Т. 18, № 2. — С. 142–147. / Bartosh F.L., Bartosh L.F., Adonina T.S. Peculiarities of left ventricular diastolic function in essential hypertensive patients with atrial fi brillation // Arterial Hypertension [Arterialnaya Gipertenziya]. — 2012. — Vol. 18, № 2. — P. 142–147 [Russian].
19. Барсуков А.В., Зобнина М.П., Багаева З.В. Гипертрофия левого желудочка при артериальной гипертензии: в фокусе проблемы — актуальные вопросы прогноза // Материалы четырнадцатой науч.-практич. конф. «Диагностика и лечение нарушений регуляции сердечно-сосудистой системы». — М., 2012. — С. 227–231. / Barsukov A.V., Zobnina M.P., Bagaeva Z.V. Left ventricular hyperetrophy in essential hypertension: actual
20. questions of prognosis is in focus of the problem // Materials of fourteenth scientifi c-practical conference «Diagnostic and treatment of cardiovascular system regulation disturbances». — Moscow, 2012. — P. 227–231 [Russian].
21. Azzam Z.S., Saldias F.J., Comellas A., Ridge K.M., Rutschman D.H., Sznajder J.I. Catecholamines increase lung edema clearance in rats with increased left atrial pressure // J. Appl. Physiol. — 2001. — Vol. 90, № 3. — Р. 1088–1094.
22. Dietz J.R. Mechanisms of atrial natriuretic peptide secretion from the atrium // Cardiovasc. Res. — 2005. — Vol. 68, № 1. — P. 8–17.
23. Cheeivia A.N., Ahmed M.W., Kadish A.H., Goldberger J.J. Effects of autonomic stimulation and blockade on signal-averaged P wave duration // J. Am. Coll. Cardio1. — 1995. — Vol. 26, № 2. — P. 497–502.
24. Gami A.S., Hodges D.O., Herges R.M. et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fi brillation // J. Am. Coll. Cardiol. — 2007. — Vol. 49, № 5. — P. 565–571. ew onset diabetes mellitus on development of atrial fibrillation and
25. Baranchuk A., Healey J., Simpson C. et al. Atrial overdrive pacing in sleep apnea: a meta-analysis // Europace. — 2009. — Vol. 11, № 8. — P. 1037–1040.
26. Akutsu Y., Kaneko K., Kodama Y. et al. Sympathetic function by mIBG and permanent AF // J. Am. Coll. Cardiol., Cardiovasc. Imaging. — 2011. — Vol. 4, № 1. — P. 78–86.
27. Dorian P., Singh B.N. Upstream therapies to prevent atrial fibrillation // Eur. Heart J. — 2008. — Vol. 10, suppl. H. — P. H11–H3.
28. Kurdi M., Booz G.W. New Take on the Role of angiotensin II in cardiac hypertrophy and fi brosis // Hypertension. — 2011. — Vol. 57, № 6. — P. 1034–1038.
29. Xu J., Carretero O.A., Liao T.D. et al. Local angiotensin II aggravates cardiac remodeling in hypertension // Am. J. Physiol. Heart Circ. Physiol. — 2010 — Vol. 299, № 5. — P. H1328–H1338.
30. L’Allier P.L., Ducharme A., Keller P., Yu H., Guertin M.C., Tardif J.C. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fi brillation // J. Am. Coll. Cardiol. — 2004. — Vol. 44, № 1. — P. 159–164.
31. Di Zhang A., Soukaseum C., Escoubet B. et al. Crosstalk between mineralocorticoid and angiotensin II signaling for cardiac remodeling // Hypertension. — 2008. — Vol. 52, № 6. — P. 1060–1067.
32. Yagi S., Akaike M., Aihara K. et al. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury // Hypertension. — 2010. — Vol. 55, № 4. — P. 918–923.
33. Nakamura T., Kataoka K., Fukuda M. et al. Critical role of apoptosis signal-regulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fi brosis // Hypertension. — 2009. — Vol. 54, № 3. — P. 544–551.
34. Kuwahara F., Tokuda K., Kai H. et al. Hypertensive myocardial fi brosis and diastolic dysfunction: another model of inflammation? // Hypertension. — 2004. — Vol. 43, № 4. — P. 739–745.
35. Graf K., Schaefer-Graf U.M. Is Smad3 the key to inflammation and fibrosis in hypertensive heart disease? // Hypertension. — 2010. — Vol. 55, № 5. — P. 1088–1089.
36. Boldt A., Wetzel U., Weigl J. et al. Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease // J. Am. Coll. Cardiol. — 2003. — Vol. 42, № 10. — P. 1785–1792.
37. McEwan P., Gray G., Cherry L. et al. Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis // Circulation. — 1998. — Vol. 98, № 24. — P. 2765–2773.
38. Nakashima H., Kumagai K., Urata H. et al. Angiotensin II antagonist prevents electrical remodeling in atrial fi brillation // Circulation. — 2000. — Vol. 101, № 22. — P. 2612–2617.
39. Lijnen P., Petrov V. Introduction of cardiac fibrosis by aldosterone // J. Mol. Cell. Cardiol. — 2000. — Vol. 32, № 6. — P. 865–879.
40. Stumpf W. Steroid hormones and the cardiovascular system direct actions of estradiol, progesterone, testosterone, gluco- and mineralcorticoids, and soltriol [vitamin D] on central nervous regulatory and peripheral tissues // Experimentia. — 1990. — Vol. 46, № 1. — P. 13–25.
41. Watson T., Karthikeyan V.J., Lip G. et al. Atrial fibrillation in primary aldosteronism // J. Renin-Ang-Ald. System. — 2009. — Vol. 10, № 4. — P. 190–194.
42. Oakley C. Genesis of arrhythmias in the failing heart and therapeutic implications // Am. J. Cardiol. — 1991. — Vol. 67, № 12. — P. 26C–28C.
43. Goette A., Staack T., Rocken C. et al. Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fi brillation // J. Am. Coll. Cardiol. — 2000. — Vol. 35, № 6. — P. 1669–1677.
44. Барсуков А.В., Глуховской Д.В., Гордиенко А.В. и др. Особенности состояния ренин-ангиотензин-альдостероновой системы и инсулинорезистентности у пациентов с артериальной гипертензией в зависимости от геометрических особенностей левого предсердия // Врач-Аспирант. — 2012. — Т. 1, № 4. — С. 123–132. / Barsukov A.V., Glukhovskoy D.V., Gordienko A.V. et al. Peculiarities of renin-angiotensin-aldosteron system and insulin resistance state in essential hypertension patients depending on geometric features of left atrium // Physician-postgraduate Student [Vrach-aspirant]. — 2012. — Vol. 1, № 4. — P. 123–132 [Russian].
45. Doronin S.V., Potarova I.A., Lu Z. et al. Angiotensin receptor type 1 forms a complex with the transient outward potassium channel Kv4.3 and regulates its gating properties and intracellular localization // J. Biol. Chem. — 2004. — Vol. 279, № 46. — P. 48231–48237.
46. Tagawa H., Wang N., Narishige T., Ingber D.E., Zile M.R., Cooper G. 4th. Cytoskeletal mechanics in pressure-overload cardiac hypertrophy // Circulat. Res. — 1997. — Vol. 80, № 2. — P. 281–289.
47. Nattel S. Driver regions in atrial fi brillation associated with congestive heart failure: where are they, and what are they telling us? // J. Cardiovasc. Electrophysiol. — 2005. — Vol. 16, № 12. — P. 1359–1361.
48. Ausma J., Litjens N., Lenders M.H. et al. Time course of atrial fi brillation-induced cellular structural remodeling in atria of the goat // J. Mol. Cell. Cardiol. — 2001. — Vol. 33, № 12. — P. 2083–2094.
49. Ausma J., Coumans W.A., Duimel H., Van der Vusse G.J., Allessie M.A., Borgers M. Atrial high energy phosphate content and mitochondrial enzyme activity during chronic atrial fi brillation // Cardiovasc. Res. — 2000. — Vol. 47, № 4. — Р. 788–796.
50. Watanabe T., Takeishi Y., Hirono O. et al. C-reactive protein elevation predicts the occurrence of atrial structural remodeling in patients with paroxysmal atrial fi brillation // Heart Vessels. — 2005. — Vol. 20, № 2. — P. 45–49.
51. Dernellis J., Panaretou M. Left atrial function in patients with a high C-reactive protein level and paroxysmal atrial fi brillation // Acta Cardiol. — 2006. — Vol. 61, № 5. — P. 507–511.
52. Rutter M. K., Meiqs J.B., Sullivan L.M. et al. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham offspring study // Circulation. — 2004. — Vol. 110, № 4. — P. 380–385.
53. Garanty-Bogacka B., Syrenicz M., Syrenicz A. et al. Relation of acute-phase reaction and endothelial activation to insulin resistance and adiposity in obese children and adolescents // Neuro Endocrinol. Lett. — 2005. — Vol. 26, № 5. — P. 473–479.
54. Henareh L., Jogestrand T., Agewall S. Glucose intolerance is associated with c-reactive protein and intima-media anatomy of the common carotid artery in patients with coronary heart disease // Diabet. Med. — 2005. — Vol. 22, № 9. — P. 1212–1217.
55. Moran A., Steffen Lyn M., Steinberger J. et al. Relation of c-reactive protein to insulin resistance and cardiovascular risk factors in youth // Diabetes Care. — 2005. — Vol. 28, № 7. — P. 1763–1768.
56. D’Alessandris C., Lauro R., Presta I. et al. C-reactive protein induces phosphorylation of insulin receptor substrate-1 on Ser (307) and Ser (612) in L6 myocytes, thereby impairing the insulinsignalling pathway that promotes glucose transport // Diabetologia. — 2007. — Vol. 50, № 4. — P. 840–849.
57. Свёклина Т.С. Комплексная клинико-анамнестическая, лабораторно-инструментальная и прогностическая оценка больных артериальной гипертензией в сочетании с сахарным диабетом 2 типа и фибрилляцией предсердий: автореф. дис.…канд. мед. н. — СПб., 2011. — 24 с. / Sveklina T.S. Complex clinico-anamnestic, labarotory-instrumental and prognostic assessment of essential hypertension patients in combination with type 2 diabetes mellitus and atrial fibrillation: abstract of thesis of Сandidate’s dissertation. — St Petersburg, 2011. — 24 p. [Russian].
58. Насонов Е.Л., Панюкова Е.В., Александрова Е.Н. С-реактивный белок — маркер воспаления при атеросклерозе (новые данные) // Кардиология. — 2002. — T. 42, № 7. — С. 53–62. / Nasonov E.L., Panyukova E.V., Alexandrova E.N. C-reactive protein — marker of inflammation in atherosclerosis (new data) // Cardiology [Kardiologiia]. — 2002. — Vol. 42, № 7. — P. 53–62 [Russian].
59. Festa A., D’Agostino R., Howard G. et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS) // Circulation. — 2000. — Vol. 102, № 1. — P. 42–47.
60. Тарасова О.А. Роль маркеров воспаления при фибрилляции предсердий // Врач-Аспирант. — 2007. — Т.16, № 1. — С. 49–53. / Tarasova O.A. The role of infl ammation markers in atrial fi brillation // Physician-Postgraduate student [Vrach-aspirant]. — 2012. — Vol.12, № 1 — P. 49–53 [Russian].
61. Барсуков А.В., Свёклина Т.С., Шустов С.Б. Показатели гормонально-регуляторной активности жировой ткани у больных артериальной гипертензией в сочетании с сахарным диабетом 2 типа и/или фибрилляцией предсердий // Вестник Российской Военно-медицинской академии. — 2011. — № 2, прил. — С. 41. / Barsukov A.V., Sveklina T.S., Shustov S.B. Parameters of hormonal-regulatory fat tissue activity in essential hypertension patients in combination with type 2 diabetes mellitus and/or atrial fi brillation // Announcer of Military Medical Academy (Vestnik Voenno-meditsinskoy Аkademii). — 2011. — № 2 (Appendix). — P. 41 [Russian].
62. Burstein B., Nattel S. Atrial fi brosis: mechanisms and clinical relevance in atrial fi brillation // Am. J. Coll. Cardiol. — 2008. — Vol. 51, № 8. — P. 801–809.
63. Yu W., Chen S., Lee S. et al. Tachycardia-induced change of atrial refractory period in humans: rate dependency and effects of antiarrhythmic drugs // Circulation. — 2006. — Vol. 97. — P. 2331–2337.
64. Madu E. C., Baugh D.S., Gbadebo T.D. et al. Effect of ethnicity and hypertension on atrial conduction: evaluation with high-resolution P-wave signal averaging // Clin. Cardiol. — 2001. — Vol. 24, № 9. — P. 597–602.
65. Shang L.L., Sanyal S., Pfahnl A.E. et al. NF- B-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II // Am. J. Physiol. Cell. Physiol. — 2008. — Vol. 294, № 1. — P. 372–379.
66. Kasi V.S., Xiao H.D., Shang L.L. et al. Cardiac-restricted angiotensin-converting enzyme overexpression causes conduction defects and connexin dysregulation // Am. J. Physiol. Heart Circ. Physiol. — 2007. — Vol. 293, № 1. — P. H182–H192.
67. Татарский Б.А., Казенова Н.В., Серебряков Н.В. Прямой блокатор ренина при лечении пароксизмальной формы фибрилляции предсердий // Артериальная гипертензия. — 2010. — Т. 16, № 1. — С. 74–81. / Tatarskiy B.A., Kazenova N.V., Serebryakov N.V. Direct renin blocker in the treatment of atrial fi brillation // Arterial Hypertension [Arterialnaya Gipertenszyia]. — 2012. — Vol. 16, № 2. — P. 74–81 [Russian].
68. Houmsse M., Tyler J., Kalbfl eisch S. Supraventricular tachycardia causing heart failure // Curr. Opinion. Cardiol. — 2011. — Vol. 26, № 3. — P. 261–269.
69. Bett G.C., Sachs F. Cardiac mechanosensitivity and stretch-activated ion channels // Trends Cardiovasc. Med. — 1997. — Vol. 7, № 1. — P. 4–8.
70. Sarubbi B., Ducceschi V., D’Andrea A. et al. Atrial fi brillation: what are the effects of drug therapy on the effectiveness and complications of electrical cardioversion? // Can. J. Cardiol. — 1998. — Vo1. 14, № 10. — P. 1267–73.
71. Zeng T., Bett G., Sachs F. Stretch-activated whole cell currents in cardiac myocytes // Am. J. Physiol. — 2000. — Vol. 278, № 2. — P. H548–H557.
72. Kamkin A., Kiseleva I., Wagner K.D. et al. Mechanoelectric feedback in right atrium after ventricular infarction in rats // J. Mol. Cell. Cardiol. — 2000. — Vol. 33, № 3. — P. 465–477.
73. Zhang J., Qin Y., Zheng X. et al. The relationship between human serum resistin level and body fat content, plasma glucose as well as blood pressure // Zhonghua Yi Xue Za Zhi. — 2002. — Vol. 82, № 23. — P. 1609–1612.
74. Камкин А.Г., Киселева И.С., Ярыгин В.Н. Ионные механизмы механоэлектрической обратной связи у клеток сердца // Успехи физиол. наук. — 2001. — Т. 32. — С. 75–104. / Kamkin A.G., Kiselev I.S., Yarygin V.N. Ionic mechanisms of mechanoelectric fi dback in cardiomyocites // Successes of physiological sciences (Uspehi Fisiologicheskih Nauk). — 2001. — Vol. 32. — P. 75–104 [Russian].
75. Gershlick A. H. Treating the non-electrical risks of atrial fi brillation // Eur. Heart J. — 1997. — Vol. 18, Suppl. C. — P. 19–26.
76. Барсуков А.В., Глуховской Д.В., Бабанова А.Я., Зобнина М.П. Особенности ремоделирования левого предсердия у пациентов с артериальной гипертензией в зависимости от состояния углеводного обмена // Сб. науч. работ врачей 442 ОВКГ МО РФ. — СПб., 2011. — С. 289. / Barsukov A.V., Glukhovskoy D.V., Babanova A.Y., Zobnina M.P. Peculiarities of left atrial remodeling in essential hypertension patients depending on carbohydrate exchange state // Collection of the scientifi c papers of physicians of 442 OVKG MO RF. — St Petersburg, 2011. — P. 289 [Russian].
Review
For citations:
Barsukov A.V., Glukhovskoy D.V., Zobnina N.P., Talantseva M.S., Sveklina T.S. LEFT ATRIUM AND MODERN VIEWS ON PATHOGENESIS OF ESSENTIAL HYPERTENSION. "Arterial’naya Gipertenziya" ("Arterial Hypertension"). 2013;19(1):18-26. (In Russ.) https://doi.org/10.18705/1607-419X-2013-19-1-18-26
Views:
2746
Email this article 